Daiwa Securities Group Inc. Has $106,000 Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Daiwa Securities Group Inc. boosted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 32.4% in the fourth quarter, HoldingsChannel reports. The fund owned 62,943 shares of the company’s stock after buying an additional 15,396 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Ginkgo Bioworks were worth $106,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its position in Ginkgo Bioworks by 27.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 507,814 shares of the company’s stock worth $858,000 after acquiring an additional 109,927 shares during the period. Vanguard Group Inc. raised its stake in shares of Ginkgo Bioworks by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 132,316,999 shares of the company’s stock worth $239,494,000 after purchasing an additional 4,016,221 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its stake in shares of Ginkgo Bioworks by 79.2% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 115,803 shares of the company’s stock worth $210,000 after purchasing an additional 51,170 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Ginkgo Bioworks by 5.2% during the 4th quarter. Nordea Investment Management AB now owns 4,412,457 shares of the company’s stock worth $7,435,000 after purchasing an additional 216,434 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Ginkgo Bioworks by 15.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company’s stock worth $106,331,000 after purchasing an additional 7,958,613 shares in the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 39,569 shares of Ginkgo Bioworks stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the transaction, the insider now directly owns 761,737 shares of the company’s stock, valued at approximately $921,701.77. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 39,569 shares of Ginkgo Bioworks stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the transaction, the insider now directly owns 761,737 shares of the company’s stock, valued at approximately $921,701.77. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark E. Dmytruk sold 51,169 shares of Ginkgo Bioworks stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the completion of the transaction, the insider now directly owns 865,079 shares in the company, valued at $908,332.95. The disclosure for this sale can be found here. Company insiders own 15.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. TD Cowen cut their price target on Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. The Goldman Sachs Group cut their price target on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $2.20.

Ginkgo Bioworks Price Performance

Shares of DNA stock opened at $0.86 on Friday. The stock’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.34. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $0.74 and a twelve month high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The company had revenue of $34.76 million during the quarter, compared to the consensus estimate of $40.37 million. During the same period in the previous year, the business posted ($0.04) earnings per share. The firm’s revenue was down 64.6% on a year-over-year basis. Analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.32 earnings per share for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.